Stomach Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults between 18 and 75 years old, of any sex
• People who have been diagnosed with advanced stomach cancer or cancer at the junction of the stomach and food pipe (confirmed by laboratory testing of tissue or cells), where the cancer stopped responding to — or caused unacceptable side effects from — the first round of treatment
• People who have at least one tumour that can be measured using standard imaging guidelines (previously treated areas with radiation cannot be counted unless the tumour has clearly grown back there)
• People with a body weight of at least 40 kg or a body mass index (BMI) above 18.5
• People whose blood counts, liver function, kidney function, and urine protein levels fall within the acceptable ranges specified by the trial (confirm with trial site for exact values)
• People with a good general level of physical functioning — able to carry out daily activities with no more than minor limitations, as rated on a standard medical scale (ECOG score of 0 or 1)
• People expected to live for at least 12 weeks
• People who have read and signed the trial's informed consent form

Who may not be able to join:

• People whose cancer tests positive for a protein called HER2, unless they have already received treatment specifically targeting HER2
• People who have had another type of cancer within the past 3 years (with exceptions for certain fully treated skin cancers or early-stage cancers of the cervix, breast, or other sites — confirm with trial site)
• People who have received certain cancer treatments — including radiation (other than for pain relief), chemotherapy, or targeted therapy — within 4 weeks before starting the trial, or within a specified timeframe based on how long the treatment stays active in the body (confirm with trial site)
• People still experiencing side effects from previous cancer treatment that have not improved to a mild level, within 2 weeks before starting the trial (hair loss is excepted; nerve-related side effects must have reduced to a moderate level)
• People who have difficulty swallowing, or who have ongoing uncontrolled nausea, vomiting, diarrhoea, or a condition that prevents the body from absorbing oral medication properly
• People with active stomach or gut conditions such as ulcers, bowel obstruction, or inflammation of the bowel, or any condition the trial doctor considers a risk for serious bleeding or gut perforation; or those who have had a gut perforation or abnormal internal opening (fistula) in the past 6 months, or have not fully recovered from surgery for these conditions
• People who have had significant or active bleeding (such as vomiting blood or coughing up blood) within the 2 months before joining; people with certain signs of gut bleeding who have not had a camera examination to rule out active bleeding or ulcers
• People who need to take stomach acid-reducing medicines (such as proton pump inhibitors or H2 blockers) long-term during the trial, or who have taken certain other medications that affect how the body processes drugs within 2 weeks before starting (confirm with trial site for specific medicines)
• People with active cancer that has spread to the brain or the lining around the brain or spinal cord
• People with active serious infections, including HIV, active hepatitis B or C, active tuberculosis, blood infections, or severe pneumonia requiring treatment (confirm with trial site for specific test thresholds)
• People who have had a heart attack, unstable chest pain, significant heart failure, or other serious heart conditions within the 6 months before starting; people with significant abnormal heart rhythm readings, reduced heart pumping function, or blood pressure that remains too high despite treatment with two or more blood pressure medicines
• People who have previously received treatments targeting a cancer growth pathway called VEGF/VEGFR, or who have previously been treated with certain chemotherapy medicines in the taxane family (such as paclitaxel or docetaxel)
• People with a known allergy to any ingredient in the trial medication
• People who are pregnant or breastfeeding
• People with fluid build-up around the lungs, abdomen, or heart that is causing symptoms and requires repeated draining
• People who have had major surgery within 4 weeks before starting the trial, or who have wounds, ulcers, or fractures that have not yet healed (in some cases, the trial doctor may approve participation from 2 weeks after surgery — confirm with trial site)
• People who have had a serious blood clot (such as in the leg or lungs) within the 3 months before joining, or who are currently taking blood-thinning medicines such as warfarin or similar agents (low-dose preventive anticoagulation may be permitted — confirm with trial site)
• People who regularly use anti-inflammatory pain medicines (such as ibuprofen or indomethacin) or blood-thinning medicines that affect platelets (such as clopidogrel); low-dose aspirin of 325 mg or less per day is generally permitted
• People the trial doctor considers unsuitable for any other reason

Important: Always verify eligibility with the trial site directly before applying.